Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Lilly declares third-quarter 2025 dividend
11:37am, Monday, 23'rd Jun 2025
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common
Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora
Lilly expects orforglipron obesity results in third quarter
09:06am, Saturday, 21'st Jun 2025
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron
Final Trade: LLY, SHEL, USO, WMT
06:21pm, Friday, 20'th Jun 2025
The final trades of the day with the Fast Money traders.
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
03:45pm, Friday, 20'th Jun 2025
Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
01:07pm, Friday, 20'th Jun 2025
Shares in Verve Therapeutics (VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly (LLY -2.60%) to acquire Verve. The deal centers on an exciting cardiovascular health medicin
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
10:31am, Friday, 20'th Jun 2025
LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:00am, Friday, 20'th Jun 2025
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
This AI Trader Bought Meta Stock and Dumped Eli Lilly
06:34am, Friday, 20'th Jun 2025
Traders now can have an AI stockpicker make those tough investment decisions
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
04:51am, Friday, 20'th Jun 2025
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
11:26am, Thursday, 19'th Jun 2025
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
5 Growth Stocks to Invest $1,000 in Right Now
03:55am, Thursday, 19'th Jun 2025
While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle East, now can still be a good time to invest in growth stocks. Investors just
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of V
